RYTM News and Press, Rhythm Pharmaceuticals Inc. From 11/04/20

-- Interim d ata from Phase 2 study showed that once-weekly formulation of setmelanotide achieve d safety and efficacy results comparable to daily-dosing formulation -- -- Additional data from long-term extension study in POMC deficiency obesity ...

Rhythm Pharmaceuticals (RYTM): Q3 GAAP EPS of -$0.77.Cash, cash equivalents and short-term investments of $201.8M.Shares are up 8.9% PM.Press Release For further details see: Rhythm Pharmaceuticals reports Q3 results

-- NDA for setmelanotide for POMC and LEPR deficiency obesities under review, with PDUFA goal date of November 27, 2020 -- -- Appointed Jennifer Chien and Yann Mazabraud to co-lead global integrated commercial strategies -- -- On track to announce topline data...

BOSTON, Oct. 30, 2020 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a late-stage biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders of obesity, announced today that results from two pivotal Phase 3 studie...

BOSTON, Oct. 28, 2020 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a late-stage biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders of obesity, today announced that Jennifer Chien has been appointed as Ex...

– Company announces organizational changes designed to accelerate global strategy – BOSTON, Sept. 14, 2020 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a late-stage biopharmaceutical company aimed at developing and commercializing therapies for the...

BOSTON, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a late-stage biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders of obesity, today announced that company management will present at tw...

Gainers:  VBI Vaccines (NASDAQ: VBIV ) +35% . More news on: VBI Vaccines Inc., Rekor Systems, Inc., BMC Stock Holdings, Inc., Stocks on the move, , Read more ...

BOSTON, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a late-stage biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders of obesity, today announced that David Meeker, M.D., Chair, President a...

Rhythm Pharmaceuticals (NASDAQ: RYTM ) : Q2 GAAP EPS of -$0.71 beats by $0.12 . More news on: Rhythm Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...